Abeona Therapeutics Inc. (NASDAQ:ABEO) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 20, 2025 Abeona Therapeutics Inc. beats earnings expectations. Reported EPS is $-0.24, ...
AFN5d
RFK Jr takes aim at self-GRAS process, but what does it mean in practice?
Proposals to eliminate the self-affirmed GRAS pathway have sent shockwaves through the food industry. But what do they mean ...
RedHill Biopharma Ltd.: RedHill Biopharma to Submit FDA-Approved Talicia for UK Marketing Authorisation
RedHill plans to submit UK MAA1 for Talicia for H. pylori infection, using MHRA's2 new fast-track approval process, referencing FDA approval, with potential UK approval ...
Healthcare Dive5d
Dr. Oz stresses need for faster Medicare coverage of new devices during confirmation hearing
Mehmet Oz, President Trump’s pick to lead the CMS, said Medicare beneficiaries should have quicker access to new medical ...
New Food Magazine1d
RFK’s push for food safety reform: experts analyse the debate over GRAS
Explore RFK Jr's push for GRAS reform and its impact on food safety. Experts David Acheson and Dr Darin Detwiler discuss ...
The Manila Times5d
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS
FILSPARI REMS: Due to the risk of hepatotoxicity and embryo-fetal toxicity, FILSPARI is available only through a restricted program called the FILSPARI REMS. Prescribers, patients, and pharmacies must ...
Green Queen2d
Self-GRAS Uncertainty Looms Over Food Tech Leaders As FDA Spotlights ‘Transparency’
RFK Jr's attack on the self-affirmed GRAS pathway could shake up the fermentation protein sector, as the FDA prioritises ...
Rasmussen Reports4dOpinion
The FDA Can Save Lives by Keeping Copycat Drugs Off the Market
For decades, the United States has led the world in pharmaceutical innovation -- developing drugs that combat cancer, heart ...
'We've Been Getting Picked Off': Product Liability Lawsuits Are Struggling
Attorney Simon Purnell of Griffin Purnell said he thinks the courts' view of preemption is a "fundamental misunderstanding of ...
GlobalData on MSN1d
BD treats first subject in trial of bioabsorbable scaffold
BD treated the first subject in the trial with GalaFLEX LITE Scaffold for reducing the recurrence of CC during breast ...
1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street
Iovance Biotherapeutics (NASDAQ: IOVA) is a biotech company with an innovative approach to developing cancer medicines. Here's what investors need to know about this small-cap biotech company. Iovance ...